Elizabeth Barrett is recorded as CEO and Board Member at UroGen Pharma Ltd. (URGN). The newest filing on record that lists Elizabeth Barrett as CEO and Board Member at UroGen Pharma Ltd. (URGN) is dated April 30, 2026. UroGen Pharma Ltd. reported in an 8-K filed June 23, 2026 that Elizabeth Barrett was appointed Director, effective June 22, 2026. UroGen Pharma Ltd. reported in an 8-K filed August 27, 2025 that Elizabeth Barrett was appointed director, effective August 26, 2025. UroGen Pharma Ltd. reported in an 8-K filed August 8, 2024 that Elizabeth Barrett was appointed director, effective August 6, 2024. Equibles holds 4 filed executive changes naming Elizabeth Barrett; each is listed under recent activity with its source filing. The proxy statement of UroGen Pharma Ltd. reports total compensation of $4,310,624 for Elizabeth Barrett in fiscal 2025, including a base salary of $855,590. Disclosed compensation is on record for 7 fiscal years. Elizabeth Barrett has spoken on 6 earnings calls across 1 company, most recently for UroGen Pharma Ltd. on November 6, 2025. UroGen Pharma Ltd. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at UroGen Pharma Ltd. includes Arie Belldegrun (Chairman and Board Member), Chris Degnan (CFO), Dong (Don) Kim (CFO) and 7 others.
“The shareholders elected the following seven individuals to serve as directors until the Company’s next annual meeting of shareholders and until their successors are elected.”
UroGen Pharma Ltd. Form 8-K, filed June 23, 2026
· Read the filing
“The shareholders elected the following seven individuals to serve as directors until the Company’s next annual meeting of shareholders and until their successors are elected.”
UroGen Pharma Ltd. Form 8-K, filed August 27, 2025
· Read the filing
Elizabeth Barrett on recent calls
“I'd like to address what I know is on everyone's mind, and that is the progress of the ZUSDURI launch. While we had expected a faster uptake, there are many factors that support our belief that the near- and long-term opportunity for ZUSDURI is on track.”
“As we look ahead to 2024, we have several near-term catalysts, including the plan release of the 12-month duration of response data from the ENVISION study in June with our expected NDA submission this year.”
“2023 was a very successful year for UroGen, laying the groundwork for progress and growth in the years ahead. The Phase III ATLAS and ENVISION trial evaluating our lead development candidate, UGN-102, both met their primary endpoints.”
“Before we remark on the quarter, I must mention the October 7 attack in Israel and its impact on our Israeli colleagues, partners, and investors. The safety of our employees is and will continue to be top of mind.”
“UroGen remains focused on developing novel therapies for urothelial and specialty cancers with the goal of fundamentally transforming the treatment paradigm for what we believe is a largely underserved patient population.”
